Shuttle Pharmaceuticals Holdings (SHPH) Amortizatization of Intangibles (2022 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Amortizatization of Intangibles of $12122.0 for Q1 2026, up 85.49% year-over-year from $6535.0 in Q1 2025, and down 12.92% quarter-over-quarter from $13921.0 in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $12122.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 85.49% year-over-year to $12122.0; the TTM figure through Mar 2026 stood at $659978.0 (up 3.05% YoY), while the FY2025 annual figure was $62030.0, down 94.25% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $12122.0, down from $13921.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $606974.0 in Q3 2022, with the low at -$508121.0 in Q4 2022.
- The 5-year median for Amortizatization of Intangibles is $316967.5 (2024), against an average of $265399.4.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles surged 337.84% in 2023, then tumbled 98.53% in 2025.
- Shuttle Pharmaceuticals Holdings' Amortizatization of Intangibles stood at -$508121.0 in 2022, then soared by 192.17% to $468325.0 in 2023, then tumbled by 47.17% to $247430.0 in 2024, then slumped by 94.37% to $13921.0 in 2025, then dropped by 12.92% to $12122.0 in 2026.
- Business Quant data shows SHPH's Amortizatization of Intangibles at $12122.0 in Q1 2026, $13921.0 in Q4 2025, and $247430.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 900,000.00 |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.89 Mn | 1.89 Mn | - | 12,122.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12,122.00 |
| Mar 31, 2026 | 12,122.00 |
| Dec 31, 2025 | 13,921.00 |
| Dec 31, 2025 | 13,921.00 |
| Sep 30, 2025 | 247,430.00 |
| Sep 30, 2025 | 247,430.00 |
| Jun 30, 2025 | 386,505.00 |
| Jun 30, 2025 | 386,505.00 |
| Mar 31, 2025 | 6,535.00 |
| Mar 31, 2025 | 6,535.00 |
| Sep 30, 2024 | 247,430.00 |
| Sep 30, 2024 | 247,430.00 |
| Jun 30, 2024 | 386,505.00 |
| Jun 30, 2024 | 386,505.00 |
| Mar 31, 2024 | 445,509.00 |
| Mar 31, 2024 | 445,509.00 |
| Dec 31, 2023 | 468,325.00 |
| Dec 31, 2023 | 468,325.00 |
| Sep 30, 2023 | 538,302.00 |
| Sep 30, 2023 | 538,302.00 |